Search results
Results From The WOW.Com Content Network
On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. ... Price Action: DXCM stock is ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. However, the rising popularity of GLP-1 drugs, which ...
The stock has historically looked expensive. Its current forward price-to-earnings ratio is 44, while the average for the healthcare industry is 17. DexCom will continue to be a volatile stock ...
At about $69 per share, DexCom's stock isn't that far off its 52-week low of $62.34 and is miles away from its 52-week high of $142. However, there remain good reasons to invest in the company ...
DXCM PE Ratio (Forward) data by YCharts. As of this writing, the healthcare industry 's average forward price-to-earnings ratio is 19.5. How much will that matter in more than 10 years, though ...
DXCM Revenue (TTM) data by YCharts. ... This makes competition on price a potent way of stealing market share, especially when the gap between options is so large. ... Stock Advisor provides ...
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
DexCom (DXCM) closed the most recent trading day at $393, moving -1.44% from the previous trading session.